Linked Life Data

2119417

Source:http://linkedlifedata.com/resource/pubmed/id/2119417

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1990-10-24
pubmed:abstractText
The efficacy and safety of a new, selective inhibitor of cholesterol synthesis, pravastatin, and the bile acid-binding resin, cholestyramine, were compared in a randomized, double-blind study of 120 patients with familial hypercholesterolaemia. After a run-in period of 8-10 weeks with assessment of dietary habits, the patients were treated with pravastatin + placebo, placebo + cholestyramine, or placebo alone. Active pravastatin therapy was initiated with 10 mg b.i.d. for 6 weeks, and was increased to 20 mg b.i.d. for the following 6 weeks. Cholestyramine was given at 24 g d-1, or the highest tolerable dose. After 6 weeks of therapy, serum total and LDL cholesterol levels were reduced by 17% and 21%, respectively, on pravastatin treatment, whereas the corresponding reductions with cholestyramine treatment were 24% and 30%, respectively. With an increased dose of pravastatin, serum and LDL cholesterol concentrations were reduced by 23% and 28%, respectively, after 12 weeks; the effect of cholestyramine was unchanged. HDL cholesterol levels increased in response to pravastatin, by 7% and 9% after 6 and 12 weeks, respectively. Concomitant changes in the concentrations of apolipoproteins B and AI were observed. Three patients discontinued the study because of side-effects: two subjects were treated with pravastatin and one was given placebo. The prevalence of side-effects (including laboratory abnormalities) was 35% for pravastatin, 30% for placebo, and 53% (significantly higher) for cholestyramine. We conclude that pravastatin, in a 40 mg daily dose, is as effective as cholestyramine in lowering LDL cholesterol in familial hypercholesterolaemia. Since the frequency of side-effects is higher with cholestyramine, pravastatin offers a promising alternative for the therapy of this genetic disease.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0954-6820
pubmed:author
pubmed:issnType
Print
pubmed:volume
228
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
241-7
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:2119417-Adult, pubmed-meshheading:2119417-Aged, pubmed-meshheading:2119417-Alanine Transaminase, pubmed-meshheading:2119417-Anticholesteremic Agents, pubmed-meshheading:2119417-Apolipoproteins, pubmed-meshheading:2119417-Aspartate Aminotransferases, pubmed-meshheading:2119417-Cholesterol, LDL, pubmed-meshheading:2119417-Cholestyramine Resin, pubmed-meshheading:2119417-Double-Blind Method, pubmed-meshheading:2119417-Female, pubmed-meshheading:2119417-Heptanoic Acids, pubmed-meshheading:2119417-Humans, pubmed-meshheading:2119417-Hyperlipoproteinemia Type II, pubmed-meshheading:2119417-Male, pubmed-meshheading:2119417-Middle Aged, pubmed-meshheading:2119417-Naphthalenes, pubmed-meshheading:2119417-Pravastatin, pubmed-meshheading:2119417-Randomized Controlled Trials as Topic, pubmed-meshheading:2119417-Triglycerides
pubmed:year
1990
pubmed:articleTitle
Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
pubmed:affiliation
Department of Medicine I, Sahlgren's Hospital, Göteborg, Sweden.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't